Morinaga Milk Obtains FDA GRAS Notification for its Probiotic
Retrieved on:
Tuesday, August 23, 2022
General Health, Consumer, Mental Health, Food, Beverage, Fitness & Nutrition, Retail, Children, Other Consumer, Baby, Maternity, Biotechnology, FDA, Health, Peanut, Food, Safety, Dairy, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Probiotic, HRB, Infant, Butter, M-63, Irritable bowel syndrome, Breast milk, International, FDA, Drink, Mental health, IBS, Health maintenance organization, GRAS, Bread, Candy, Health, General manager, Dietary supplement, Vaccine, Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp.
Key Points:
- Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp.
- Bifidobacterium infantis M-63 is a unique Human-Residential Bifidobacteria (HRB) probiotic strain with an immense capacity to utilize human milk oligosaccharide (HMOs), the component that is highly abundant in human breast milk.
- Morinaga Milk is highly committed to achieving global regulatory standards for its HRB probiotics range and became the only Japanese company to have obtained the Infant GRAS notification for its all three HRB probiotic strains.
- In addition to its GRAS approval for use in infant formula, B. infantis M-63 has also received the FDA GRAS notification for use in general foods and beverages.